The European Union's plan to fix its clinical trial system is now visible from both sides: the remedy, and the problem the remedy must solve. The remedy is the proposed European Biotech Act, published by the Commission in December 2025, which would cut the maximum authorization period for multinational clinical trials from about 106 days to 75, and to 47 days where no additional information is requested. The problem is the European Medicines Agency's first quarterly progress report on the EU's 2030 clinical trial targets, published around September 1, which showed the union authorizing trials above its historical average while still running behind the pace its own targets require. The Act promises speed the EU has never managed. The report is the first evidence of how far behind the promise starts.
The targets were set with unusual specificity. The EU wants 500 additional multinational trials authorized by the end of 2030, and it wants 66 percent of trials recruiting their first patient within 200 days. The first quarterly report, published around September 1, covered January through March 2026 and showed 19 multinational trials authorized above the historical average, which annualizes to nowhere near the pace the 500-trial target requires, and 40.5 percent of trials recruiting within 200 days against the 66 percent goal. The gap is not failure so much as confirmation: the EU trial system's bottlenecks are structural, and they are the exact bottlenecks the Biotech Act is written around.
What the Act would actually change
The centerpiece is time. The current system authorizes a multinational trial application in about 106 days at the maximum, with an additional 50-day review period for advanced therapy products. The Act would cut the main timeline to 75 days, 47 where no requests for information are issued, and remove the extra ATMP review period entirely. Substantial amendments would move from 96 days to 47, or 33 without clarification requests. These are not marginal accelerations; they are a one-third compression of the slowest step in drug development.
The second layer is procedural. The Act strengthens the lead reporting member state's role, integrates ethics review into the first part of the assessment, and builds mutual trust between member states so that one country's assessment is not redone wholesale in twenty-six others. It creates a simplified category for minimal-intervention trials using authorized products, which would need only ethics review, and a reusable core dossier for investigational products so sponsors do not rewrite the same file for every study. Electronic informed consent would be explicitly authorized, and combined trials of medicines with devices or diagnostics would get a unified assessment.
The third layer is data. The Act rewrites the data protection article of the Clinical Trials Regulation to create a single harmonized legal basis for processing trial data, designates sponsors and investigators as controllers, and prohibits member states from stacking additional national conditions on top. The European data protection authorities, in their joint opinion, supported the harmonization while demanding safeguards for sensitive health data, which is the EDPB's way of saying the direction is right and the details need work.
The proof of concept already exists
The strongest argument for the Act's feasibility is not in the proposal; it is in the pilot that ran before it. The FAST-EU pilot, operating since January 2026, moved its first three procedures through coordinated assessment in roughly 70 days, close to the Act's proposed 75-day statutory maximum, as the Regulatory Rapporteur documented. Voluntary pilots attract the easiest cases, and the pilot's results cannot prove the general system can sustain the pace, but they answer the obvious objection that European coordination is structurally incapable of moving that fast. The pilot is the Act's existence proof, and the Act's timelines are deliberately set just above what the pilot achieved.
The politics of adoption are where the uncertainty lives. Member state experts met through the summer, the European Parliament is preparing its position, and trilogue negotiations follow. The Act is expected to be adopted later this year, but every layer that touches member state authority, the ethics integration, the lead state role, the data provisions, will be contested, and the final timelines may not survive intact.
The honest accounting of what faster trials produce
The Biotech Act's premise, repeated across the Commission's supporting material, is that the EU is losing clinical research to faster jurisdictions and that trials are the foundation of the life sciences sector the union wants to rebuild. The mechanism is real: every month of trial authorization delay is a month a drug spends not generating the evidence that could reach patients, and companies site their studies where the evidence can be generated fastest. The Act is an industrial policy document wearing a regulatory costume, and its speed provisions are the industrial policy.
The counterweight is that authorization timelines are only one bottleneck in a system where recruitment, site capacity, and post-authorization operations matter as much or more. The EMA's own report makes the point implicitly: recruiting 40.5 percent of trials within 200 days against a 66 percent target is a recruitment problem, not an authorization problem, and no amount of timeline compression in Brussels recruits patients in hospital wards. The Act's drafters know this, which is why the proposal reaches beyond timelines into infrastructure, data, and the minimal-intervention category meant to shrink the burden on the least risky research.
The most honest reading of the two documents side by side is this: the report measures the system the Act is replacing, and the Act legislates the system the report says is needed. Whether the union can legislate its way from one to the other is the open question, and the first quarterly report will be the baseline against which every future report is read.
The targets, translated into patients
The 2030 targets sound administrative, and their real subject is patients. The 500 additional multinational trials the EU wants by 2030 are not a bureaucratic score; each trial is a cohort of patients gaining access to an experimental therapy through the only channel that makes such access possible. The 66 percent recruitment target measures how long a patient waits between a trial's authorization and its first enrolment, and the current 40.5 percent figure means the majority of authorized European trials are slow to open, which in patient terms is a delay in the trial that could have treated them.
The migration pressure the Act responds to is visible in sponsor behavior. Global drug developers allocate trials where they can start fastest, and the EU's historical timelines have pushed multi-regional studies toward jurisdictions with quicker starts. Every multinational trial sited in Europe is a trial European patients can join; every one sited elsewhere is one they cannot. The Biotech Act's timeline compression is, at bottom, a patient access measure wearing a competitiveness rationale, and the EMA's quarterly report is the instrument that will show whether the access is actually arriving.
The recruitment gap also exposes the limits of what Brussels can legislate. Authorization timelines are set by regulation; recruitment speed is set by hospitals, investigators, and the patients who must consent, none of which answer to a deadline in a directive. The Act can compress the regulatory timeline to 75 days or 47, and the EMA report can still show recruitment lagging the target, because the bottleneck lives downstream of anything the Act touches. The honest reading of the first report alongside the Act is that Europe needs both: faster authorization, and a recruitment system that can keep up with the faster authorization once it arrives.
The politics of the Act's final passage will be decided this year, and the first quarterly report will be cited on both sides of the trilogue. Supporters will read the gap between target and performance as the case for speed. Skeptics will read the same gap as proof that the system's problems are not the ones the Act solves. Both readings are defensible, which is usually the sign that a reform is aimed at the right system and incomplete about the rest of it.
The sequence to watch is now fixed. The Parliament's position, the trilogue, the final timelines, and then the quarterly reports measuring the system the Act was meant to fix. The first report of that series already exists, and it reads like a baseline taken before treatment: 19 trials above average, recruitment at 40.5 percent against 66, and a 500-trial target receding into the distance. The Act is Europe's answer to that baseline. Whether the baseline moves is the only metric that will matter, and it will be published every three months.
Primary sources
- PharmaNow coverage of the EMA's first quarterly EU clinical trial progress report.
- JD Supra analysis of the proposed Biotech Act one hundred days on.
- Regulatory Rapporteur on the FAST-EU pilot's 70-day timelines.
- Press Club coverage of the EDPB/EDPS joint opinion on the Act's data provisions.